BioSpace News Archive

Sapience Therapeutics, Inc. presented new clinical and biomarker data from its ST101 Phase 2 study in GBM at the 2024 American Society of Clinical Oncology Annual Meeting.

CStone Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, which is one of the largest cancer indications and a leading cause of cancer death in the world.

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib in combination with a SHP2 inhibitor in frontline non-small cell lung cancer patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology Annual Meeting as form of oral presentation.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-253 Phase 1 trial.

TiumBio Co., Ltd. announced interim results from the Phase 1b clinical trial of TU2218 in combination with pembrolizumab at the 2024 American Society of Clinical Oncology Annual Meeting.

Boehringer Ingelheim’s new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company’s inhalers is now available.

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence -enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer.

Werewolf Therapeutics, Inc. announced new clinical data from the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINETM molecule, in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced that it is presenting a Trial in Progress poster for the phase 1 ANCHOR clinical trial at the 2024 American Society of Clinical Oncology Annual Meeting being held May 31 – June 4, 2024 in Chicago, IL.

Immunocore Holdings plc presented three posters about KIMMTRAK® for the treatment of patients with unresectable or metastatic uveal melanoma at the 2024 ASCO Annual Meeting.